🔎 Trials Near Me

Hjem › Burkitts lymfom › Alabama

Burkitts lymfom kliniske forsøg i Alabama

7 studier for Burkitts lymfom søger deltagere på steder i Alabama.

Byer i Alabama

Officiel studietekst (engelsk)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital of Alabama, Birmingham
RekruttererFase 2
366 Days – 46 Years · Alle køn · Opdateret 2. okt. 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's Hospital of Alabama, Birmingham
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
RekruttererFase 2
Alder 1 til 30 · Alle køn · Opdateret 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. nov. 2025 · NCT04260022

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
RekruttererFase 2
Alder 1 til 25 · Alle køn · Opdateret 4. maj 2025 · NCT03509961

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. nov. 2024 · NCT06034275

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.